Terrein: isolation, chemical synthesis, bioactivity and future prospects of a potential therapeutic fungal metabolite

The increasing risk of drug-resistant infections and unexpected pandemics like Covid-19 has prompted researchers to explore the area of drug repurposing. Natural products, being a result of the evolutionary optimisation processes can be potential starting points for such drug discovery programs. One such unexplored chemical is terrein, a secondary fungal metabolite. Although discovered in 1935 from Aspergillus terreus, the therapeutic potential of terrein has largely remained undeciphered. Research has primarily been focused on its biosynthetic pathways and its mycotoxic effects. However, in the last two decades, its biological properties including anticancer, anti-inflammatory anti-melanogenic, and bacteriocidal activities have been reported. These reports are preliminary in nature and do not adequately establish its overall therapeutic application. From its structural and therapeutic properties, it can be conjectured that terrein may act as a novel multimodal therapeutic. This comprehensive study reviews the synthesis, production and application aspects of terrein to understand its importance.